Literature DB >> 24990879

Functional genomics for personalized cancer therapy.

Jeffrey W Tyner1.   

Abstract

Integration of functional and genomic screening strategies reveals clinically actionable genetic events that impact the effectiveness of cancer treatment regimens and the outcomes of cancer patients.
Copyright © 2014, American Association for the Advancement of Science.

Entities:  

Mesh：

Year:  2014        PMID： 24990879      PMCID： PMC5266503          DOI： 10.1126/scitranslmed.3009586

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN： 1946-6234            Impact factor:   17.956


  10 in total

1.  Ligand independence of the T618I mutation in the colony-stimulating factor 3 receptor (CSF3R) protein results from loss of O-linked glycosylation and increased receptor dimerization.

Authors:  Julia E Maxson; Samuel B Luty; Jason D MacManiman; Melissa L Abel; Brian J Druker; Jeffrey W Tyner
Journal:  J Biol Chem       Date:  2014-01-08       Impact factor: 5.157

2.  The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor.

Authors:  Michael Hudecek; Thomas M Schmitt; Sivasubramanian Baskar; Maria Teresa Lupo-Stanghellini; Tetsuya Nishida; Tori N Yamamoto; Marie Bleakley; Cameron J Turtle; Wen-Chung Chang; Harvey A Greisman; Brent Wood; David G Maloney; Michael C Jensen; Christoph Rader; Stanley R Riddell
Journal:  Blood       Date:  2010-08-11       Impact factor: 22.113

3.  Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia.

Authors:  F Dong; R K Brynes; N Tidow; K Welte; B Löwenberg; I P Touw
Journal:  N Engl J Med       Date:  1995-08-24       Impact factor: 91.245

4.  Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.

Authors:  Rocco Piazza; Simona Valletta; Nils Winkelmann; Sara Redaelli; Roberta Spinelli; Alessandra Pirola; Laura Antolini; Luca Mologni; Carla Donadoni; Elli Papaemmanuil; Susanne Schnittger; Dong-Wook Kim; Jacqueline Boultwood; Fabio Rossi; Giuseppe Gaipa; Greta P De Martini; Paola Francia di Celle; Hyun Gyung Jang; Valeria Fantin; Graham R Bignell; Vera Magistroni; Torsten Haferlach; Enrico Maria Pogliani; Peter J Campbell; Andrew J Chase; William J Tapper; Nicholas C P Cross; Carlo Gambacorti-Passerini
Journal:  Nat Genet       Date:  2012-12-09       Impact factor: 38.330

5.  Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia.

Authors:  Vincent T Bicocca; Bill H Chang; Behzad Kharabi Masouleh; Markus Muschen; Marc M Loriaux; Brian J Druker; Jeffrey W Tyner
Journal:  Cancer Cell       Date:  2012-11-13       Impact factor: 31.743

6.  RNAi screen for rapid therapeutic target identification in leukemia patients.

Authors:  Jeffrey W Tyner; Michael W Deininger; Marc M Loriaux; Bill H Chang; Jason R Gotlib; Stephanie G Willis; Heidi Erickson; Tibor Kovacsovics; Thomas O'Hare; Michael C Heinrich; Brian J Druker
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-11       Impact factor: 11.205

7.  Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening.

Authors:  Jeffrey W Tyner; Wayne F Yang; Armand Bankhead; Guang Fan; Luke B Fletcher; Jade Bryant; Jason M Glover; Bill H Chang; Stephen E Spurgeon; William H Fleming; Tibor Kovacsovics; Jason R Gotlib; Stephen T Oh; Michael W Deininger; Christian Michel Zwaan; Monique L Den Boer; Marry M van den Heuvel-Eibrink; Thomas O'Hare; Brian J Druker; Marc M Loriaux
Journal:  Cancer Res       Date:  2012-10-18       Impact factor: 12.701

8.  ROR1 can interact with TCL1 and enhance leukemogenesis in Eμ-TCL1 transgenic mice.

Authors:  George F Widhopf; Bing Cui; Emanuela M Ghia; Liguang Chen; Karen Messer; Zhouxin Shen; Steven P Briggs; Carlo M Croce; Thomas J Kipps
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-30       Impact factor: 11.205

9.  Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.

Authors:  Julia E Maxson; Jason Gotlib; Daniel A Pollyea; Angela G Fleischman; Anupriya Agarwal; Christopher A Eide; Daniel Bottomly; Beth Wilmot; Shannon K McWeeney; Cristina E Tognon; J Blake Pond; Robert H Collins; Basem Goueli; Stephen T Oh; Michael W Deininger; Bill H Chang; Marc M Loriaux; Brian J Druker; Jeffrey W Tyner
Journal:  N Engl J Med       Date:  2013-05-09       Impact factor: 91.245

10.  In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia.

Authors:  Jason M Glover; Marc Loriaux; Jeffrey W Tyner; Brian J Druker; Bill H Chang
Journal:  Pediatr Blood Cancer       Date:  2011-10-28       Impact factor: 3.167
  10 in total
  6 in total

1.  Prospective analysis of 895 patients on a UK Genomics Review Board.

Authors:  David Allan Moore; Marina Kushnir; Gabriel Mak; Helen Winter; Teresa Curiel; Mark Voskoboynik; Michele Moschetta; Nataliya Rozumna-Martynyuk; Kevin Balbi; Philip Bennett; Martin Forster; Anjana Kulkarni; Debra Haynes; Charles Swanton; Hendrik-Tobias Arkenau
Journal:  ESMO Open       Date:  2019-03-21

Review 2.  Models of cardiovascular surgery biobanking to facilitate translational research and precision medicine.

Authors:  YingYan Zhu; Dan Jackson; Benjamin Hunter; Lorna Beattie; Lisa Turner; Brett D Hambly; Richmond W Jeremy; Cassandra Malecki; Elizabeth N Robertson; Amy Li; Cris Dos Remedios; David Richmond; Christopher Semsarian; John F O'Sullivan; Paul G Bannon; Sean Lal
Journal:  ESC Heart Fail       Date:  2021-12-21

Review 3.  Emerging roles of exosomal miRNAs in diabetes mellitus.

Authors:  Xiaoyun He; Gaoyan Kuang; Yongrong Wu; Chunlin Ou
Journal:  Clin Transl Med       Date:  2021-06

4.  Can kinomics and proteomics bridge the gap between pediatric cancers and newly designed kinase inhibitors?

Authors:  Naomi E van der Sligte; Kim R Kampen; Eveline S J M de Bont
Journal:  Cell Mol Life Sci       Date:  2015-08-31       Impact factor: 9.261

5.  Dissecting tRNA-derived fragment complexities using personalized transcriptomes reveals novel fragment classes and unexpected dependencies.

Authors:  Aristeidis G Telonis; Phillipe Loher; Shozo Honda; Yi Jing; Juan Palazzo; Yohei Kirino; Isidore Rigoutsos
Journal:  Oncotarget       Date:  2015-09-22

6.  "Direct to Drug" screening as a precision medicine tool in multiple myeloma.

Authors:  Cecilia Bonolo de Campos; Nathalie Meurice; Joachim L Petit; Alysia N Polito; Yuan Xiao Zhu; Panwen Wang; Laura A Bruins; Xuewei Wang; Ilsel D Lopez Armenta; Susie A Darvish; Greg J Ahmann; Kimberly J Henderson; Shulan Tian; Jonas J Kruse; William M Stewart; Jeremy T Larsen; Craig B Reeder; David Dingli; Prashant Kapoor; Shaji K Kumar; Rafael Fonseca; P Leif Bergsagel; Esteban Braggio; A Keith Stewart
Journal:  Blood Cancer J       Date:  2020-05-11       Impact factor: 11.037
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.